Brief: MGC Pharmaceuticals Posts HY Net Loss Attributable A$7.1 Million Versus Loss A$10.9 Million
29/02/2024 08:39
Feb 29 (Reuters) - MGC Pharmaceuticals Ltd MXC.AX :
* HY NET LOSS ATTRIBUTABLE A$7.1 MILLION VERSUS LOSS A$10.9
MILLION
Source text for Eikon: ID:nASX6jVlS0
Further company coverage: MXC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group